New Brazilian-developed brain tumor drug to begin in hospital testing
By the end of March patients at the Federal Hospital in Ipanema, in Rio de Janeiro, Brazil, will begin taking part in the decisive phase of testing for new chemotherapy drug, Brazil’s Ministry of Health has announced.
The drug is being tested for the treatment of the most common type of malignant brain tumor. The product, which was researched, developed and patented by the Federal Fluminense University (UFF) in Rio de Janeiro, increases survival among patients and the prospects for successful treatment.
This work involved the strict observance of procedures related to research ethics. The patients have full knowledge of the activities and sign the terms of informed consent before participating in the research, the Ministry statement noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze